Everest Pharmaceuticals Ltd.
Abemaciclib Cancer (oncology)
Originator: Verzenio · Eli Lilly and Company (Lilly USA, LLC)
| Brand | Strength | Form |
|---|---|---|
| Abemaxen | 150 mg and 200 mg tablets | — |
Alectinib Cancer (oncology)
Originator: Alecensa · Roche (Genentech in the US; originated by Chugai Pharmaceutical)
| Brand | Strength | Form |
|---|---|---|
| Alecnib | 150 mg capsule | — |
| Alecnib | 150 mg | Capsule |
Baricitinib Immunology & rheumatology
Originator: Olumiant · Eli Lilly and Company (co-developed with Incyte; initial U.S. approval 2018)
| Brand | Strength | Form |
|---|---|---|
| Barixen | 2 mg | Tablet |
Capmatinib Cancer (oncology)
Originator: Tabrecta · Novartis (discovered by Incyte, licensed to Novartis in 2009)
| Brand | Strength | Form |
|---|---|---|
| Capmaxen | 200 mg | Tablet |
Crizotinib Cancer (oncology)
Originator: Xalkori · Pfizer
| Brand | Strength | Form |
|---|---|---|
| Alkixen | 250 mg capsule | — |
| Alkixen | 250 mg | Capsule |
Empagliflozin Diabetes & metabolic
Originator: Jardiance · Boehringer Ingelheim, co-marketed with Eli Lilly and Company (licensed from Boehringer Ingelheim International GmbH)
| Brand | Strength | Form |
|---|---|---|
| Empoli | 10 mg | Tablet |
| Empoli | 25 mg | Tablet |
Ibrutinib Cancer (oncology)
Originator: Imbruvica · Pharmacyclics LLC (an AbbVie company) and Janssen Biotech, Inc. (Johnson & Johnson) - developed and commercialised jointly; US distributor of record: Pharmacyclics LLC
| Brand | Strength | Form |
|---|---|---|
| Ibruxen | 140 mg capsule | — |
| Ibruxen | 140 mg | Capsule |
Lorlatinib Cancer (oncology)
Originator: Lorbrena · Pfizer Inc.
| Brand | Strength | Form |
|---|---|---|
| Lorbrexen | 100 mg tablet | — |
| Lorbrexen | 100 mg | Tablet |
Niraparib Cancer (oncology)
Originator: Zejula · GlaxoSmithKline (GSK); originally developed by Tesaro (Tesaro UK Limited)
| Brand | Strength | Form |
|---|---|---|
| Niranib | 100 mg capsule | — |
| Niranib | 100 mg | Capsule |
Olaparib Cancer (oncology)
Originator: Lynparza · AstraZeneca (distributed by AstraZeneca Pharmaceuticals LP); developed and commercialised in collaboration with Merck (MSD outside the US and Canada)
| Brand | Strength | Form |
|---|---|---|
| Olanib | 150 mg tablet and 50 mg capsule | — |
| Olanib | 150 mg | Tablet |
| Olanib | 50 mg | Capsule |
Osimertinib Cancer (oncology)
Originator: Tagrisso · AstraZeneca
| Brand | Strength | Form |
|---|---|---|
| Osimert | 80 mg tablet | — |
| Osimert | 80 mg | Tablet |
Palbociclib Cancer (oncology)
Originator: Ibrance · Pfizer Inc. (Pfizer Laboratories Div Pfizer Inc)
| Brand | Strength | Form |
|---|---|---|
| Palboxen | 125 mg capsule | — |
| Palboxen | 125 mg | Capsule |
Sofosbuvir/Velpatasvir Antivirals (hepatitis C)
Originator: Epclusa · Gilead Sciences (Gilead Sciences Ireland UC for the EU)
| Brand | Strength | Form |
|---|---|---|
| Velpanex | 400 mg + 100 mg tablet | — |
| Velpanex | 400 mg+100 mg | Tablet |
Tofacitinib Immunology & rheumatology
Originator: Xeljanz / Xeljanz XR · Pfizer (initial U.S. approval 2012)
| Brand | Strength | Form |
|---|---|---|
| Tofaxen | 5 mg | Tablet |
This page is an information resource for healthcare professionals, licensed importers and patients under medical care. It is not medical advice, not a prescription service, and not an offer to sell prescription medicines to the public.
Need a verified quotation?
Send us the molecule, strength, pack size, quantity and destination country. We reply with a batch-traceable quotation, certificates of analysis and shipping documentation.
We supply licensed pharmacies, hospitals, importers and distributors — not direct-to-consumer patients.
